Notes:

Excluded pts. w/ high-grade carotid artery stenosis.

An ongoing trial, the Warfarin Aspirin Recurrent Stroke Study (WARSS) is comparing a lower target INR (1.4 - 2.8) to 325 mg ASA in a similar population.

A second ongoing trial, Stroke Prevention with Warfarin and Aspirin Trial (SWAT) by A. Shuaib is comparing 1300 mg ASA vs. 80 mg ASA + INR 2-3.

There may also be a 3rd trial, similar to SPIRIT, in Europe & Australia.

Back

Contents

Next

This presentation was authored by Dr. Brian Gage of the Washington University School of Medicine.